Israel Englander Aligos Therapeutics, Inc. Transaction History

Millennium Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.35 - $1.07 $28,273 - $86,434	-80,780 Reduced 73.0%	29,881 $10,000
Q1 2024 May 15, 2024	BUY	$0.64 - $1.13 $52,451 - $92,610	81,956 Added 285.51%	110,661 $108,000
Q4 2023 Feb 14, 2024	SELL	$0.56 - $0.8 $82,415 - $117,736	-147,170 Reduced 83.68%	28,705 $18,000
Q2 2023 Aug 14, 2023	SELL	$0.89 - $1.36 $202,470 - $309,393	-227,495 Reduced 56.4%	175,875 $170,000
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $27,884 - $67,627	32,051 Added 8.63%	403,370 $353,000
Q4 2022 Feb 14, 2023	BUY	$0.89 - $28.0 $34,877 - $1.1 Million	39,188 Added 11.8%	371,319 $354,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $27.5 $140,214 - $3.64 Million	-132,278 Reduced 28.48%	332,131 $365,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.66B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.